<unk>  produces considerably less virilization in women compared to equal doses of testosterone propionate. However, since the given dosage for breast cancer was relatively high (200mg/twice a week), mild virilization including oily skin, acne, voice deepening, hirsutism, and clitoral enlargement could still occur, and marked virilization could manifest with long-term therapy. The drug has no estrogenic activity and hence has no propensity for causing gynecomastia (in males) or fluid retention.<unk>  is not known to pose a risk of hepatotoxicity.
Drostanolone propionate
Androstanolone propionate
Androstanolone benzoate
Androstanolone valerate
Nandrolone cyclohexylpropionate
Nandrolone furylpropionate
Androstanolone enanthate
Nandrolone phenylpropionate